Valuation: EyePoint, Inc.

Market Cap 1.2B 1.04B 967M 887M 1.67B 114B 1.7B 11.35B 4.45B 57.12B 4.5B 4.4B 189B P/E 2026 *
-3.61x
P/E 2027 * -4.72x
Enterprise Value 875M 757M 707M 648M 1.22B 83.25B 1.24B 8.29B 3.25B 41.73B 3.28B 3.21B 138B EV / Sales 2026 *
476x
EV / Sales 2027 * 32.7x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day+7.92%
1 month-6.84%
3 months-2.68%
6 months+1.96%
Current year-27.96%
1 week 9.8
Extreme 9.8
10.9
1 month 9.8
Extreme 9.8
12.6
Current year 9.45
Extreme 9.45
15.27
1 year 8.47
Extreme 8.466
15.32
3 years 3.52
Extreme 3.525
28.6
5 years 2.08
Extreme 2.08
28.6
10 years 0.38
Extreme 0.382
35.98
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Change 5-day change 1-year change 3-year change Capi.($)
+7.92%0.00% - - 1.2B
-0.52%+3.21%+89.52%+127.32% 1,057B
+0.88%+1.13%+49.56%+49.69% 625B
+0.89%-1.95%+24.23%+64.44% 435B
+0.71%+3.87%+49.07%+37.85% 363B
+0.64%-0.49%+33.94%+40.01% 296B
+0.39%-5.83%+8.92%+7.85% 249B
+1.51%+6.69%+42.58%+57.57% 222B
+3.92%-0.46%-5.56%-52.32% 209B
+1.80%+2.30%+11.56%+66.35% 165B
Average +1.81%+0.87%+33.76%+44.31% 402.31B
Weighted average by Cap. +0.66%+1.22%+48.72%+64.63%

Financials

2026 *2027 *
Net sales 1.84M 1.59M 1.48M 1.36M 2.56M 175M 2.6M 17.41M 6.83M 87.64M 6.9M 6.75M 290M 25.52M 22.08M 20.61M 18.91M 35.57M 2.43B 36.13M 242M 94.93M 1.22B 95.83M 93.74M 4.02B
Net income -346M -299M -279M -256M -482M -32.92B -490M -3.28B -1.29B -16.5B -1.3B -1.27B -54.55B -288M -249M -233M -214M -402M -27.45B -408M -2.73B -1.07B -13.76B -1.08B -1.06B -45.48B
Net Debt -323M -279M -261M -239M -450M -30.72B -457M -3.06B -1.2B -15.4B -1.21B -1.19B -50.91B -362M -313M -292M -268M -504M -34.45B -512M -3.43B -1.35B -17.27B -1.36B -1.33B -57.08B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change
07/08/26 €10.90 +7.92%
06/08/26 €10.10 +2.02%
05/08/26 €9.900 -4.81%
04/08/26 €10.40 0.00%
03/08/26 €10.40 -4.59%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
13.89USD
Average target price
40.93USD
Spread / Average Target
+194.66%

Quarterly revenue - Rate of surprise